NMRA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 113561 min ago

@ $18.19

Išleistas: 14 vas. 2024 @ 19:07

Grąža: -48.21%

Ankstesnis signalas: vas. 14 - 18:05

Ankstesnis signalas: Pardavimas

Grąža: -1.41 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 16:48):

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases...

Stats
Šios dienos apimtis	46 167.00
Vidutinė apimtis	591 941
Rinkos kapitalizacija	1.50B
EPS	$0 ( 2024-03-13 )
Kita pelno data	( $-0.350 ) 2024-06-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.60
ATR14	$0.0190 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-08	Arch Venture Partners Xii, Llc	Buy	1 176 593	Common Stock
2023-12-08	Arch Venture Partners Xii, Llc	Buy	703 061	Common Stock
2023-12-08	Arch Venture Partners X, Llc	Buy	1 176 593	Common Stock
2023-12-08	Arch Venture Partners X, Llc	Buy	703 061	Common Stock
2023-12-08	Burow Kristina	Buy	1 176 593	Common Stock

INSIDER POWER
35.64
Last 85 transactions
Buy: 48 806 253 \| Sell: 23 661 663

Tūris Koreliacija

Ilgas: -0.04 (neutral)

Trumpas: -0.29 (neutral)

Signal:(52.562) Neutral

Neumora Therapeutics, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Neumora Therapeutics, Koreliacija - Valiuta/Žaliavos

-0.71
( moderate negative )

0.00
( neutral )

-0.72
( moderate negative )

-0.65
( moderate negative )

0.64
( weak )

Neumora Therapeutics, Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-0.860

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-0.860

Financial Reports:

No articles found.

Neumora Therapeutics,

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.